Drugs / IDX184
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01157104 | Jun → Jul 2010 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00730431 | Jul → Oct 2008 | hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00807001 | Dec 2008 → Jul 2009 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01371604 | Jul 2011 → Mar 2013 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT01011166 | Nov 2009 → Jul 2010 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDX184 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01157104 ↗ |
| Action | Inhibit | “a potent and specific polymerase inhibitor of the hepatitis C virus (HCV).” PMID 21060109 ↗ Nov 2010 |
| Modality | Other / unclassified | “IDX184 is a nucleotide prodrug designed” PMID 21060109 ↗ Nov 2010 |
| Route | Oral | “single ascending oral doses of 5, 10, 25, 50, 75, and 100 mg IDX184 were administered” PMID 21060109 ↗ Nov 2010 |